

Attorney Docket No.: RTS-0325
Inventors: Bennett and Wyatt
Serial No.: 10/016,149
Filing Date: November 1, 2001
Page 2

The following listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

Claim 1 (currently amended): An antisense oligonucleotide 8 to 50 nucleobases in length targeted to nucleobases ~~703 through 969~~ through 992 of a 3'-untranslated region of a nucleic acid molecule encoding human phospholipase A2 group V (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding phospholipase A2 group V and inhibits the expression of phospholipase A2 group V, and wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claims 2-4 (canceled).

Claim 5 (previously presented): The compound of claim 1 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (previously presented): The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

BEST AVAILABLE COPY

Attorney Docket No.: RTS-0325
Inventors: Bennett and Wyatt
Serial No.: 10/016,149
Filing Date: November 1, 2001
Page 3

Claim 8 (previously presented): The compound of claim 1 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (previously presented): The compound of claim 1 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (previously presented): A method of inhibiting the expression of phospholipase A2 group V in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of phospholipase A2 group V is inhibited.

Claims 16-18 (canceled).

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY. As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.